225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced…
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response…
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas Blue Water Biotech Expands Commercial…
With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval– Company believes CAL02 is a…
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatmentsLEHI,…
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded…
Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients Paris, June 13, 2023. Sanofi…
Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of ovarian cancer during a panel…
Rebecca Skvorc named Chief Financial OfficerJim Diefenbach named SVP of SalesMike Goulart named Sr. Director, Business AccelerationTORONTO, June 06, 2023…
Elicio completes reverse merger, becoming a publicly traded company on the Nasdaq stock exchangePositive Phase 1 clinical data was recently…